反应详情

Prepared according to procedure Y using tert-butyl 4-(4-chloro-5,7-difluoro-3-methylquinolin-2-yl)piperazine-1-carboxylate (690.0 mg, 1.70 mmol) and 6′-morpholino-1′,2,2′,3,5,6-hexahydrospiro[pyran-4,3′-pyrrolo[3,2-b]pyridine] in toluene to give tert-butyl 4-(5,7-difluoro-3-methyl-4-(6′-(4-morpholinyl)-2,3,5,6-tetrahydrospiro[pyran-4,3′-pyrrolo[3,2-b]pyridin]-1′(2′H)-yl)-2-quinolinyl)-1-piperazinecarboxylate. 1H NMR (400 MHz, chloroform-d) δ ppm 7.56 (1H, d, J=2.3 Hz), 7.35 (1H, ddd, J=9.8, 2.4, 1.1 Hz), 6.75 (1H, ddd, J=11.8, 8.9, 2.5 Hz), 5.66 (1H, d, J=2.3 Hz), 4.05-4.22 (2H, m), 3.80-3.98 (2H, m), 3.71-3.79 (4H, m), 3.48-3.71 (6H, m), 3.24-3.44 (4H, m), 2.89-3.06 (4H, m), 2.26-2.43 (2H, m), 2.25 (3H, s), 1.64-1.87 (3H, m), 1.51 (9H, s). Mass Spectrum (ESI) m/e=637.5 (M+1).

1. customPrepared